Abstracts tagged "Scleroderma"

Abstract Number: 0880 • ACR Convergence 2025
Detecting Interstitial Lung Disease and Identifying Extensive Disease on Chest Computed Tomography in Patients with Systemic Sclerosis: Cut-Offs for Lung Texture Analysis and its Prognostic Implications
Nicholas landini¹, lisa Jungblut², cecilia strappa³, Christian Blüthgen², Rucsandra Dobrota⁴, Muriel Elhai⁵, Carina Mihai⁶, Sinziana Muraru-Carbune², Martina Orlandi⁷, mariaelena Occhipinti⁸, Khadija El-Aoufy⁹, Gemma Lepri¹⁰, valeria panebianco¹¹, anna rita larici³, Anna-Maria Hoffmann-Vold¹², Cosimo Nardi¹³, Serena Guiducci¹⁴, Silvia Bellando-Randone¹⁵, Marco Matucci-Cerinic¹⁶, Thomas Frauenfelder², Oliver Distler¹⁷ and Cosimo Bruni¹⁸, ¹Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Rueil Malmaison, France, ²Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, zurich, Switzerland, ³Advanced Radiology Center, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy, rome, Italy, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁵Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Schlieren, Switzerland, ⁶University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia School of Medicine, Italy., modena, Italy, ⁸Division of Radiology, Fondazione Toscana Gabriele Monasterio, Pisa, Italy., pisa, Italy, ⁹Department of Health Science, University of Florence, Florence, Italy., firenze, Italy, ¹⁰Department of Experimental and Clinical Medicine, University of Florence, Division of Rheumatology Scleroderma Unit, AOU Careggi Hospital, Florence, Italy., Florence, Italy, ¹¹Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy., Rome, Italy, ¹²Oslo University Hospital, Oslo, Norway, ¹³Department of Experimental and Clinical Biomedical Sciences, Radiodiagnostic Unit n. ², University of Florence - Azienda Ospedaliero-Universitaria Careggi, Florence, Italy, Florence, Italy, ¹⁴Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, Pistoia, Italy, ¹⁵University of Florence, Florence, Florence, Italy, ¹⁶University San Raffaele Milano, Milano, Milan, Italy, ¹⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹⁸University of Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of death in patients with systemic sclerosis (SSc), especially in case of extensive disease detected on…
Abstract Number: PP04 • ACR Convergence 2025
MCTD and Aging – Resilience Required
Carol Kaminski
Background/Purpose: I was diagnosed with MCTD at age 25. My priorities were understanding a disease I had trouble pronouncing, and trying to learn to live with…
Abstract Number: 1952 • ACR Convergence 2025
Dermatoscopy Limitation and the Critical Role of Capillaroscopy in Systemic Sclerosis and Raynaud’s Phenomenon among African American Veterans
Genessis Maldonado¹, Maurizio Cutolo², Tracy Frech¹, Mislav Radic³, Marcus Snow⁴ and Vanessa Smith⁵, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Genova, Genova, Italy, ³University Hospital Split, Division of Rheumatology and Clinical Immunology, Split, Croatia, Split, Croatia, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Ghent University Hospital, Gent, Belgium
Background/Purpose: Nailfold capillaroscopy (NFC) is an essential tool for evaluating microvascular abnormalities in patients with Raynaud’s phenomenon (RP) in United States (U.S.) Veterans (1). While…
Abstract Number: 1565 • ACR Convergence 2025
Association of the gastrointestinal (GI) microbiome and GI symptoms in systemic sclerosis: An international, multi-center, observational study
Zsuzsanna McMahan¹, Swapna Joshi², Jennifer Labus², Arissa Young², Andrea Low³, Vanessa Smith⁴, Susanna Proudman⁵, Antonia Valenzuela⁶, Phoebe Hunter⁷, Kristofer Andréasson⁸, Ezinne Aja², Jonathan Jacobs² and Elizabeth Volkmann⁹, ¹UT Health Houston, Houston, TX, ²UCLA, Los Angeles, ³Singapore General Hospital, SingHealth; Duke-NUS, Singapore, Singapore, ⁴Ghent University Hospital, Gent, Belgium, ⁵Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ⁶Pontificia Universidad Catolica de Chile, Santiago, Chile, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸Skåne University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ⁹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: GI disease is highly prevalent in systemic sclerosis (SSc) and adversely affects quality of life and survival in SSc. The pathogenesis of GI disease…
Abstract Number: 0955 • ACR Convergence 2025
Surveying RNA methylation in scleroderma highlights roles for demethylases ALKBH5 and FTO in fibrosis
Alexander Cai¹, Alyssa Rosek¹, Neha Khanna¹, Anna Webber¹, Karly Kozicki¹, Dinesh Khanna² and Pei-Suen Tsou², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Recent studies indicate that genes involved in RNA methylation may play a significant role in cellular functions, and disruptions in RNA methylation have been…
Abstract Number: 0846 • ACR Convergence 2025
A Longitudinal Transcriptomic Study of Mycophenolate Mofetil in Systemic Sclerosis Skin with Clinical and Molecular Stratification
Rezvan Parvizi¹, Zhiyun Gong², Natania Field³, Helen Jarnagin², Dillon Popovich², Monica Yang⁴, Kathleen Aren⁵, Mary Carns⁶, Isaac Goldberg⁷, Lorinda Chung⁸, Vivien Goh⁹, Zsuzsanna McMahan¹⁰, Tammara Wood¹¹, Dinesh Khanna¹², Monique Hinchcliff¹³ and Michael Whitfield¹⁴, ¹Dartmouth, lebanon, NH, ²Dartmouth College, Lebanon, NH, ³Northwestern Memorial Hospital, Chicago, IL, ⁴UCSF, San Francisco, CA, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶Northwestern University, Chicago, IL, ⁷Wayne State University, Detroit, ⁸Stanford University, Stanford, CA, ⁹Northwestern, Chicago, ¹⁰UT Health Houston, Houston, TX, ¹¹Dartmouth, Hanover, NH, ¹²University of Michigan, Ann Arbor, MI, ¹³Yale School of Medicine, Westport, CT, ¹⁴Geisel School of Medicine, Lebanon, NH
Background/Purpose: Mycophenolate Mofetil (MMF) is the most commonly prescribed immunosuppressive treatment for patients diagnosed with diffuse cutaneous systemic sclerosis (dcSSc). Here, we analyzed skin gene…
Abstract Number: 2654 • ACR Convergence 2025
Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis
Ellen Romich¹, Alexis Ogdie², Alisa Stephens Shields², Peter Merkel², Jessica Alvey³, Shervin Assassi⁴, Elana Bernstein⁵, Sonali Bracken⁶, Flavia Castelino⁷, Lorinda Chung⁸, Luke Evnin⁹, Tracy Frech¹⁰, Jessica Gordon¹¹, Faye Hant¹², Monica Harding¹³, Laura Hummers¹⁴, Dinesh Khanna¹⁵, Kimberly Lakin¹¹, Dorota Lebiedz-Odrobina¹³, Yiming Luo⁵, Ashima Makol¹⁶, Maureen Mayes¹⁷, Zsuzsanna McMahan¹⁸, Jerry Molitor¹⁹, Duncan Moore²⁰, Carrie Richardson²¹, Ami Shah¹⁴, Ankoor Shah²², Brian Skaug²³, Virginia Steen²⁴, John VanBuren¹³, Elizabeth Volkmann²⁵, Carleigh Zahn¹⁵ and Nora Sandorfi², ¹University of Pennsylvania, Media, PA, ²University of Pennsylvania, Philadelphia, PA, ³Utah Data Coordinating Center, University of Utah, Salt Lake City, UT, ⁴Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁵Columbia University, New York, NY, ⁶Duke University Medical Center, Durham, NC, USA, Apex, NC, ⁷Massachusetts General Hospital, Boston, MA, ⁸Stanford University, Stanford, CA, ⁹Scleroderma Research Foundation, San Francisco, CA, ¹⁰Vanderbilt University Medical Center, Nashville, TN, ¹¹Hospital for Special Surgery, New York, NY, ¹²Medical University of South Carolina, Charleston, SC, ¹³University of Utah, Salt Lake City, UT, ¹⁴Johns Hopkins Rheumatology, Baltimore, MD, ¹⁵University of Michigan, Ann Arbor, MI, ¹⁶Mayo Clinic, Rochester, MN, ¹⁷UT Health Houston Division of Rheumatology, Houston, TX, ¹⁸UT Health Houston, Houston, TX, ¹⁹University of Minnesota, Minneapolis, MN, ²⁰Northwestern Memorial Hospital, Chicago, IL, ²¹Northwestern University, Chicago, IL, ²²Duke University, Durham, NC, ²³UTHealth Houston Division of Rheumatology, Houston, TX, ²⁴Georgetown University School of Medicine, Washington, DC, ²⁵Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: To determine the frequency and extent of discordance between patient and physician global assessments of disease in early systemic sclerosis and identify factors associated…
Abstract Number: 1906 • ACR Convergence 2025
The incidence and mortality of connective tissue diseases in England: a population-level cohort study from 2012 to 2023
Samir Patel¹, Mark Russell¹, Katie Bechman¹, Maryam Adas¹, Zijing Yang¹, Edward Alveyn¹, Chris Wincup², Alexandru Dregan¹, Kate Bramham¹, Sam Norton¹, James Galloway¹ and Patrick Gordon¹, ¹King's College London, London, United Kingdom, ²King's College Hospital, London, United Kingdom
Background/Purpose: The reported incidence and mortality of connective tissue diseases (CTDs) in England has been inconsistent in the literature. Our objective was to describe current…
Abstract Number: 1566 • ACR Convergence 2025
Factors Associated with Patient and Physician Global Assessments in Early Systemic Sclerosis
Ellen Romich¹, Alexis Ogdie², Peter Merkel³, Alisa Stephens Shields³, Jessica Alvey⁴, Shervin Assassi⁵, Elana Bernstein⁶, Sonali Bracken⁷, Flavia Castelino⁸, Lorinda Chung⁹, Luke Evnin¹⁰, Tracy Frech¹¹, Jessica Gordon¹², Faye Hant¹³, Monica Harding¹⁴, Laura Hummers¹⁵, Dinesh Khanna¹⁶, Kimberly Lakin¹², Dorota Lebiedz-Odrobina¹⁴, Yiming Luo⁶, Ashima Makol¹⁷, Maureen Mayes¹⁸, Zsuzsanna McMahan¹⁹, Jerry Molitor²⁰, Duncan Moore²¹, Carrie Richardson²², Ami Shah¹⁵, Ankoor Shah²³, Brian Skaug²⁴, Virginia Steen²⁵, John VanBuren¹⁴, Elizabeth Volkmann²⁶, Carleigh Zahn¹⁶ and Nora Sandorfi³, ¹University of Pennsylvania, Media, PA, ²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ³University of Pennsylvania, Philadelphia, PA, ⁴Utah Data Coordinating Center, University of Utah, Salt Lake City, UT, ⁵Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁶Columbia University, New York, NY, ⁷Duke University Medical Center, Durham, NC, USA, Apex, NC, ⁸Massachusetts General Hospital, Boston, MA, ⁹Stanford University, Stanford, CA, ¹⁰Scleroderma Research Foundation, San Francisco, CA, ¹¹Vanderbilt University Medical Center, Nashville, TN, ¹²Hospital for Special Surgery, New York, NY, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴University of Utah, Salt Lake City, UT, ¹⁵Johns Hopkins Rheumatology, Baltimore, MD, ¹⁶University of Michigan, Ann Arbor, MI, ¹⁷Mayo Clinic, Rochester, MN, ¹⁸UT Health Houston Division of Rheumatology, Houston, TX, ¹⁹UT Health Houston, Houston, TX, ²⁰University of Minnesota, Minneapolis, MN, ²¹Northwestern Memorial Hospital, Chicago, IL, ²²Northwestern University, Chicago, IL, ²³Duke University, Durham, NC, ²⁴UTHealth Houston Division of Rheumatology, Houston, TX, ²⁵Georgetown University School of Medicine, Washington, DC, ²⁶Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: Global assessments by patients and physicians provide unique but complementary perspectives of disease severity. This study aimed to determine the clinical and patient-reported factors…
Abstract Number: 0710 • ACR Convergence 2025
Vascular Events in Systemic Sclerosis Patients with Anti-Phospholipid Antibodies
Vivian Shing¹, Emily Thompson², Emma Terwilliger³, Simran Ravindra Nimal⁴, Alejandro Diaz Arumir Vergara², Michael Pham⁴ and Vivek Nagaraja⁴, ¹Mayo Clinic Alix School of Medicine, Scottsdale, AZ, ²Mayo Clinic, Scottsdale, ³Mayo Clinic Alix School of Medicine, Scottsdale, ⁴Mayo Clinic, Scottsdale, AZ
Background/Purpose: APS is a pro-thrombotic autoimmune condition often associated with other systemic autoimmune rheumatic diseases (SARDs), most notably SLE. The link between aPL positivity and…
Abstract Number: 0845 • ACR Convergence 2025
Machine Learning–Based Skin Transcriptome Classifier (v2.0) Links SSc Molecular Subtypes to Disease Severity and Progression
Zhiyun Gong¹, Rezvan Parvizi², Helen Jarnagin¹, Haobin Chen³, Madeline Morrisson⁴, Tammara Wood⁵, Monique Hinchcliff⁶, Dinesh Khanna⁷ and Michael Whitfield⁸, ¹Dartmouth College, Lebanon, NH, ²Dartmouth, lebanon, NH, ³Dartmouth Collge, Lebanon, NH, ⁴Geisel School of Medicine at Dartmouth College, Hanover, NH, ⁵Dartmouth, Hanover, NH, ⁶Yale School of Medicine, Westport, CT, ⁷University of Michigan, Ann Arbor, MI, ⁸Geisel School of Medicine, Lebanon, NH
Background/Purpose: Systemic Sclerosis (SSc) is a clinically and molecularly heterogeneous autoimmune disease. We identified five intrinsic molecular subtypes in SSc by applying semi-supervised machine learning…
Abstract Number: 2651 • ACR Convergence 2025
Development and Validation of the Scleroderma Clinical Trials Consortium Classification Criteria for Systemic Sclerosis Heart Involvement
Laura Ross¹, Andrew Burns², Andre La Gerche³, Dylan Hansen⁴, Gerry Coghlan⁵, Wendy Stevens⁶, David Prior⁷, Alan Pham⁸, Penelope McKelvie⁴, Chiara Bellocchi⁹, Yolanda Braun Moscovici¹⁰, Cosimo Bruni¹¹, Patricia E. Carreira¹², Tracy Frech¹³, Sabrina Hoa¹⁴, Marie Hudson¹⁵, Vivien Hsu¹⁶, Marco Matucci-Cerinic¹⁷, Benjamin Medina Fonseca¹⁸, Andrea Low¹⁹, Sue-Ann Ng¹⁹, Tatiana Rodriguez-Reyna²⁰, Joanne Sahhar²¹, Mohamed Talaat²², Susanna Proudman²³, Alessandra Vacca²⁴, Murray Baron²⁵ and Mandana Nikpour²⁶, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²St Vincent's Hospital Melbourne, Fitzroy, Australia, ³St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia, ⁴St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, ⁵Royal Free Hospital, London, United Kingdom, ⁶St Vincent's Hospital Melbourne & University of Melbourne, Fitzroy, Australia, ⁷University of Melbourne, Parkville, Australia, ⁸Alfred Hospital, Melbourne, Australia, ⁹University of Milan, Milan, Italy, ¹⁰Rambam Heath Care Campus, Haifa, Israel, ¹¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹²Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹³Vanderbilt University Medical Center, Nashville, TN, ¹⁴University of Montreal, Brossard, QC, Canada, ¹⁵McGill University, Montréal, QC, Canada, ¹⁶Rutgers- RWJ Medical School, South Plainfield, NJ, ¹⁷University San Raffaele Milano, Milano, Milan, Italy, ¹⁸Universidad Nacional Autonoma de Mexico, Monterry, Mexico, ¹⁹Singapore General Hospital, Singapore, Singapore, ²⁰Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²¹Monash Health, Melbourne, Victoria, Australia, ²²Augusta Health, Charlottesville, VA, ²³Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ²⁴University and AOU of Cagliari, Monserrato, Italy, ²⁵McGill University, Montreal, Canada, ²⁶University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia
Background/Purpose: Systemic sclerosis (SSc) heart involvement (SHI) is a serious disease manifestation associated with high mortality. This study presents newly developed classification criteria to enable…
Abstract Number: 1873 • ACR Convergence 2025
TGF-β-Driven Mitochondrial Stress Activates cGAS-STING Signalling via Impaired Mitophagy in Systemic Sclerosis Endothelial Cells
Stefano Di Donato¹, Ceclie Bordes², Claude Lalou², agathe Depaire², John Tchen², Charlene Lhuissier², damien Brisou², Vanja Sisirak², Johan Garaude², Christopher Wasson³, Rebecca Ross⁴, Francesco Del Galdo³ and Marie-Elise Truchetet⁵, ¹University of Leeds, Canosa Sannita, Chieti, Italy, ²University of Bordeaux, Bordeaux, France, ³University of Leeds, Leeds, United Kingdom, ⁴Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁵Bordeaux University Hospital, Bordeaux, France
Background/Purpose: Emerging evidence implicates mitochondrial dysfunction as a contributor to tissue fibrosis in systemic sclerosis (SSc) (1). Endothelial cells, which are a key player in…
Abstract Number: 1562 • ACR Convergence 2025
Vasodilation with Prostanoids Influences Progression of Systemic Sclerosis-Associated Interstitial Lung Disease: a EUSTAR Cohort Study
adela cristina sarbu¹, Liubov Petelytska², lorenzo tofani³, Gianluca Moroncini⁴, Alexandra Balbir-Gurman⁵, elisabetta zanatta⁶, Jörg Henes⁷, paolo airò⁸, Marco Matucci-Cerinic⁹, Ana Maria Gheorghiu¹⁰, antonella marcoccia¹¹, branimir Anić¹², Jelena Colic¹³, Daniel Furst¹⁴, julia Spierings¹⁵, Francesco Del Galdo¹⁶, Britta Maurer¹⁷, Anna-Maria Hoffmann-Vold¹⁸, Oliver Distler¹⁹ and Cosimo Bruni²⁰, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. • Department of Rheumatology and Immunology, Bern University Hospital, University of Bern, Bern, Switzerland, bern, Swaziland, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. • Dept Internal Medicine #³, Bogomolets National Medical University, Kyiv, Ukraine, Kyiv, Ukraine, ³Department of Statistics, Informatics and Applications, University of Florence, Florence, Italy, firenze, Italy, ⁴Department of Internal Medicine, Marche University Hospital, Clinica Medica, Ancona, Italy, Ancona, Italy, ⁵• Rheumatology Institute, Rambam Health Care Campus, Rappaport Faculty of Medicine, Tecchnion, Haifa, Israel, Haifa, Israel, ⁶Padova University Hospital, Rheumatology Unit, Padova, Italy, padova, Italy, ⁷Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, ⁸Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, brescia, Italy, ⁹University San Raffaele Milano, Milano, Milan, Italy, ¹⁰Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania, ¹¹Centro di Riferimento Interdisciplinare per la Sclerosi Sistemica (CRIIS), Roma, Italy, rome, Italy, ¹²Department of Internal Medicine, Division of Clinical Immunology and Rheumatology, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Croatia, zagreb, Croatia, ¹³Institute of Rheumatology Belgrade, Belgrade, Serbia, Belgrade, Serbia, ¹⁴Southern California Scleroderma and Rheumatology Center, Los Angeles, CA, ¹⁵Department of Rheumatology & Clinical Immunology, University Medical Center, Ultrecht, The Netherlands, Utrecht, Netherlands, ¹⁶University of Leeds, Leeds, United Kingdom, ¹⁷Department of Rheumatology & Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ¹⁸Oslo University Hospital, Oslo, Norway, ¹⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ²⁰University of Zurich, Zurich, Switzerland
Background/Purpose: Although most vasoactive vasodilating drugs (VVDs) exert anti-fibrotic effects in pre-clinical studies, randomized controlled trials assessing their efficacy in systemic sclerosis-associated interstitial lung disease…
Abstract Number: 0705 • ACR Convergence 2025
Multimodal Imaging Evaluation of Patients with Raynaud’s Phenomenon meeting the Criteria for “Early” Systemic Sclerosis according to LeRoy versus Healthy Controls: a Prospective Cross-sectional study
Ramona Govender¹, Elvis Hysa², Rosanna Campitiello³, Steven Wallaert¹, Matthias Vandycke¹, Emanuele Gotelli³, Tessa Du Four¹, Maurizio Cutolo⁴ and Vanessa Smith⁵, ¹University of Ghent, Ghent, Belgium, ²University of Genoa, Genoa, Italy, ³University of Genoa, Genoa, Liguria, Italy, ⁴University of Genova, Genova, Italy, ⁵Ghent University Hospital, Gent, Belgium
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disorder. To date, no comparative multi-modal imaging data exist for precursor patients, those with Raynaud’s phenomenon (RP)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].